Piperine inhibits IL-1β-induced IL-6 expression by suppressing p38 MAPK and STAT3 activation in gastric cancer cells

Molecular and Cellular Biochemistry

Volumn 398, Issue 1-2, 2015, Pages 147-156

  Xia, Yong ^a   Khoi, Pham Ngoc ^a   Yoon, Hyun Joong ^a   Lian, Sen ^a   Joo, Young Eun ^a   Chay, Kee Oh ^a   Kim, Kyung Keun ^a   Jung, Young Do ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Gastric cancer; IL 6; p38MAPK; Piperine; STAT3

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; PIPERINE; SMALL INTERFERING RNA; STAT3 PROTEIN; 1,3 BENZODIOXOLE DERIVATIVE; ALKALOID; AMIDE; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; URIDINE DIPHOSPHATE GLUCOSE 4 EPIMERASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TMK 1 CELL LINE; TRANSCRIPTION INITIATION; TUMOR INVASION; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL MOTION; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; STOMACH TUMOR; TUMOR CELL LINE;

ALKALOIDS; BENZODIOXOLES; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; INTERLEUKIN-1BETA; INTERLEUKIN-6; MUTATION; NEOPLASM INVASIVENESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; STAT3 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS; UDPGLUCOSE 4-EPIMERASE;

EID: 84922005329     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-014-2214-0     Document Type: Article

References (55)

1. Jemal A, Center MM, DeSantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomark Prev 19:1893–1907
2. Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J, Savastano B, Mabilia A (2014) Treatment of gastric cancer. World J Gastroenterol 20:1635–1649
3. Ohshima H, Tatemichi M, Sawa T (2003) Chemical basis of inflammation-induced carcinogenesis. Arch Biochem Biophys 417:3–11
4. Cheng T-Y, Wu M-S, Hua K-T, Kuo M-L, Lin M-T (2014) Cyr61/CTGF/Nov family proteins in gastric carcinogenesis. World J Gastroenterol 20:1694–1700
5. Chung HW, Lim JB (2014) Role of the tumor microenvironment in the pathogenesis of gastric carcinoma. World J Gastroenterol 20:1667–1680
6. Lin MT, Lin BR, Chang CC, Chu CY, Su HJ, Chen ST, Jeng YM, Kuo ML (2007) IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway. Int J Cancer 120:2600–2608
7. Garbers C, Hermanns HM, Schaper F, Muller-Newen G, Grotzinger J, Rose-John S, Scheller J (2012) Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev 23:85–97
8. Guo Y, Xu F, Lu T, Duan Z, Zhang Z (2012) Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38:904–910
9. Yin Y, Si X, Gao Y, Gao L, Wang J (2013) The nuclear factor-κB correlates with increased expression of interleukin-6 and promotes progression of gastric carcinoma. Oncol Rep 29:34–38
10. Lee SA, Choi SR, Jang JS, Lee JH, Roh MH, Kim SO, Kim MC, Kim SJ, Jeong JS (2010) Expression of VEGF, EGFR, and IL-6 in gastric adenomas and adenocarcinomas by endoscopic submucosal dissection. Dig Dis Sci 55:1955–1963
11. Ashizawa T, Okada R, Suzuki Y, Takagi M, Yamazaki T, Sumi T, Aoki T, Ohnuma S (2005) Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 8:124–131
12. Wang Z, Si X, Xu A, Meng X, Gao S, Qi Y, Zhu L, Li T, Li W, Dong L (2013) Activation of STAT3 in human gastric cancer cells via interleukin (IL)-6-type cytokine signaling correlates with clinical implications. PLoS ONE 8:e75788
13. Necula LG, Chivu-Economescu M, Stanciulescu EL, Bleotu C, Dima SO, Alexiu I, Dumitru A, Constantinescu G, Popescu I, Diaconu CC (2012) IL-6 and IL-11 as markers for tumor aggressiveness and prognosis in gastric adenocarcinoma patients without mutations in Gp130 subunits. J Gastrointest Liver Dis 21:23–29
14. Jackson CB, Judd LM, Menheniott TR, Kronborg I, Dow C, Yeomans ND, Boussioutas A, Robb L, Giraud AS (2007) Augmented gp130-mediated cytokine signalling accompanies human gastric cancer progression. J Pathol 213:140–151
15. Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E (2006) The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25:387–408
16. Cahill CM, Rogers JT (2008) Interleukin (IL) 1β induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/IκB kinase α pathway targeting activator protein-1. J Biol Chem 283:25900–25912
17. Kandere-Grzybowska K, Kempuraj D, Cao J, Cetrulo CL, Theoharides TC (2006) Regulation of IL-1-induced selective IL-6 release from human mast cells and inhibition by quercetin. Br J Pharmacol 148:208–215
18. Kim HG, Han EH, Jang W-S, Choi JH, Khanal T, Park BH, Tran TP, Chung YC, Jeong HG (2012) Piperine inhibits PMA-induced cyclooxygenase-2 expression through downregulating NF-κB, C/EBP and AP-1 signaling pathways in murine macrophages. Food Chem Toxicol 50:2342–2348
19. Bae GS, Kim MS, Jeong J, Lee HY, Park KC, Koo BS, Kim BJ, Kim TH, Lee SH, Hwang SY et al (2011) Piperine ameliorates the severity of cerulein-induced acute pancreatitis by inhibiting the activation of mitogen activated protein kinases. Biochem Biophys Res Commun 410:382–388
20. Lai LH, Fu QH, Liu Y, Jiang K, Guo QM, Chen QY, Yan B, Wang QQ, Shen JG (2012) Piperine suppresses tumor growth and metastasis in vitro and in vivo in a 4T1 murine breast cancer model. Acta Pharmacol Sin 33:523–530
21. Ouyang DY, Zeng LH, Pan H, Xu LH, Wang Y, Liu KP, He XH (2013) Piperine inhibits the proliferation of human prostate cancer cells via induction of cell cycle arrest and autophagy. Food Chem Toxicol 60:424–430
22. Ge B, Gram H, Di Padova F, Huang B, New L, Ulevitch RJ, Luo Y, Han J (2002) MAPKK-independent activation of p38alpha mediated by TAB 1-dependent autophosphorylation of p38alpha. Science 295:1291–1294
23. Selvendiran K, Prince Vijeya Singh J, Sakthisekaran D (2006) In vivo effect of piperine on serum and tissue glycoprotein levels in benzo(a)pyrene induced lung carcinogenesis in Swiss albino mice. Pulm Pharmacol Ther 19:107–111
24. Pradeep CR, Kuttan G (2004) Piperine is a potent inhibitor of nuclear factor-kappaB (NF-kappaB), c-Fos, CREB, ATF-2 and proinflammatory cytokine gene expression in B16F-10 melanoma cells. Int Immunopharmacol 4:1795–1803
25. Hwang YP, Yun HJ, Kim HG, Han EH, Choi JH, Chung YC, Jeong HG (2011) Suppression of phorbol-12-myristate-13-acetate-induced tumor cell invasion by piperine via the inhibition of PKCalpha/ERK1/2-dependent matrix metalloproteinase-9 expression. Toxicol Lett 203:9–19
26. Makhov P, Golovine K, Canter D, Kutikov A, Simhan J, Corlew MM, Uzzo RG, Kolenko VM (2012) Co-administration of piperine and docetaxel results in improved anti-tumor efficacy via inhibition of CYP3A4 activity. Prostate 72:661–667
27. Pradeep C, Kuttan G (2004) Piperine is a potent inhibitor of nuclear factor-κB (NF-κB), c-Fos, CREB, ATF-2 and proinflammatory cytokine gene expression in B16F-10 melanoma cells. Int Immunopharmacol 4:1795–1803
28. Kakarala M, Brenner DE, Korkaya H, Cheng C, Tazi K, Ginestier C, Liu S, Dontu G, Wicha MS (2010) Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat 122:777–785
29. Bae G-S, Kim M-S, Jung W-S, Seo S-W, Yun S-W, Kim SG, Park R-K, Kim E-C, Song H-J, Park S-J (2010) Inhibition of lipopolysaccharide-induced inflammatory responses by piperine. Eur J Pharmacol 642:154–162
30. Kumar S, Singhal V, Roshan R, Sharma A, Rembhotkar GW, Ghosh B (2007) Piperine inhibits TNF-α induced adhesion of neutrophils to endothelial monolayer through suppression of NF-κB and IκB kinase activation. Eur J Pharmacol 575:177–186
31. Łukaszewicz-Zajac M, Mroczko B, Szmitkowski M (2010) The role of interleukin-6 and C-reactive protein in gastric cancer. Pol Merkur Lek Organ Pol Towarz Lekarskiego 29:382–386
32. Huang S-P, Wu M-S, Shun C-T, Wang H-P, Lin M-T, Kuo M-L, Lin J-T (2004) Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J Biomed Sci 11:517–527
33. Kim D-K, Oh SY, Kwon H-C, Lee S, Kwon KA, Kim BG, Kim S-G, Kim S-H, Jang JS, Kim MC (2009) Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 9:155
34. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H (2009) IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway. J Exp Med 206:1457–1464
35. Kinoshita H, Hirata Y, Nakagawa H, Sakamoto K, Hayakawa Y, Takahashi R, Nakata W, Sakitani K, Serizawa T, Hikiba Y (2013) Interleukin-6 mediates epithelial–stromal interactions and promotes gastric tumorigenesis. PLoS ONE 8:e60914
36. Lin MT, Lin BR, Chang CC, Chu CY, Su HJ, Chen ST, Jeng YM, Kuo ML (2007) IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway. Int J Cancer 120:2600–2608
37. Troost E, Hold GL, Smith MG, Chow WH, Rabkin CS, McColl KE, El-Omar EM (2003) The role of interleukin-1beta and other potential genetic markers as indicators of gastric cancer risk. Can J Gastroenterol 17 Suppl B:8B–12B
38. Tsuzaki M, Guyton G, Garrett W, Archambault J, Herzog W, Almekinders L, Bynum D, Yang X, Banes A (2003) IL-1β induces COX2, MMP-1,-3 and-13, ADAMTS-4, IL-1β and IL-6 in human tendon cells. J Orthop Res 21:256–264
39. Seger R, Krebs EG (1995) The MAPK signaling cascade. FASEB J 9:726–735
40. Johnson GL, Lapadat R (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298:1911–1912
41. Obata T, Brown GE, Yaffe MB (2000) MAP kinase pathways activated by stress: the p38 MAPK pathway. Crit Care Med 28:N67–N77
42. Do MT, Kim HG, Choi JH, Khanal T, Park BH, Tran TP, Jeong TC, Jeong HG (2013) Antitumor efficacy of piperine in the treatment of human HER2-overexpressing breast cancer cells. Food Chem 141:2591–2599
43. Craig R, Larkin A, Mingo AM, Thuerauf DJ, Andrews C, McDonough PM, Glembotski CC (2000) p38 MAPK and NF-kappa B collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system. J Biol Chem 275:23814–23824
44. Patil C, Zhu X, Rossa C Jr, Kim YJ, Kirkwood KL (2004) p38 MAPK regulates IL-1β induced IL-6 expression through mRNA stability in osteoblasts. Immunol Invest 33:213–233
45. Hideshima T, Akiyama M, Hayashi T, Richardson P, Schlossman R, Chauhan D, Anderson KC (2003) Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood 101:703–705
46. Baldassare JJ, Bi Y, Bellone CJ (1999) The role of p38 mitogen-activated protein kinase in IL-1β transcription. J Immunol 162:5367–5373
47. Petrella BL, Vincenti MP (2012) Interleukin-1β mediates metalloproteinase-dependent renal cell carcinoma tumor cell invasion through the activation of CCAAT enhancer binding protein β. Cancer Med 1:17–27
48. Liu Y, Fuchs J, Li C, Lin J (2010) IL-6, a risk factor for hepatocellular carcinoma. Cell Cycle 9:3423–3427
49. Hirano T, Ishihara K, Hibi M (2000) Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19:2548–2556
50. Mori T, Miyamoto T, Yoshida H, Asakawa M, Kawasumi M, Kobayashi T, Morioka H, Chiba K, Toyama Y, Yoshimura A (2011) IL-1β and TNFα-initiated IL-6–STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. Int Immunol 23:701–712
51. Samavati L, Rastogi R, Du W, Hüttemann M, Fite A, Franchi L (2009) STAT3 tyrosine phosphorylation is critical for interleukin 1 beta and interleukin-6 production in response to lipopolysaccharide and live bacteria. Mol Immunol 46:1867–1877
52. Bode JG, Ehlting C, Häussinger D (2012) The macrophage response towards LPS and its control through the p38(MAPK)–STAT3 axis. Cell Signal 24:1185–1194
53. Wang Y, Ren X, Deng C, Yang L, Yan E, Guo T, Li Y, Xu MX (2013) Mechanism of the inhibition of the STAT3 signaling pathway by EGCG. Oncol Rep 30:2691–2696
54. Wung B-S, Hsu M-C, Wu C-C, Hsieh C-W (2005) Resveratrol suppresses IL-6-induced ICAM-1 gene expression in endothelial cells: effects on the inhibition of STAT3 phosphorylation. Life Sci 78:389–397
55. Oyagbemi A, Saba A, Azeez O (2010) Capsaicin: a novel chemopreventive molecule and its underlying molecular mechanisms of action. Indian J Cancer 47:53–58